Ifosfamide fanconi

Maprotiline
Bidil
Docetaxel
Symmetrel

This may lead to further optimisation of the therapeutic index of ifosfamide treatment.

Five g m2 ifosfamide given intravenously as a short half hour ; or long 24 hr ; infusion does not exhibit dose dependent zero-order ; pharmacokinetics. That the benefit of ASA was restricted to individuals without a history of MI. In several studies of ASA after MI there has been a positive but nonsignificant reduction in reinfarctions and deaths, 26"29 and our result is in agreement with those experiences. However, great caution is necessary when interpreting results from subgroup analyses as the chance of spurious statistical significance is increased. In a study involving patients of such advanced ages as ours it was rewarding to learn that less than onethird of all participants were withdrawn for reasons other than reaching a primary endpoint. In previous studies of ASA after TIA or stroke the proportion of withdrawals has varied between 13 and 35%.3-6~8 As in the prior studies the most common cause of withdrawal was a drug side effect; 34% of all withdrawals compared with 24 and 35% in the Canadian and Danish studies, respectively.68 Serious side effects were rare, but 1 patient with a major stroke in the ASA group succumbed to multiple ulcers in the ventricle and the esophagus. Four randomized placebo-controlled studies have been published on the effect of ASA in the secondary prevention of stroke Table 7 ; . Two had been published when this study started, and both suggested a beneficial effect of ASA. 36 Since then, a Danish study8 has been reported that included 203 patients, of whom 25% had reversible ischemic deficit and the remainder TIA. No significant prophylactic effect of ASA could be detected in that study. In a study from France7 including 604 patients in which 84% had completed strokes, 55% with minor and 29% with moderate sequelae, patients with ASA ingestion alone or in combination with dipyridamole had a significant reduction in cerebral infarctions. In our study no beneficial effect of high-dose ASA could be found concerning the prevention of recurrent stroke or death. Thus, results from different studies. By MR JESS PERRY SI 113 1992 ; . Cham pion-twice, stakes win ner of 12 races in 21 starts of 7, 184, Texas Clas sic Fut. G1, Texas Clas sic D., etc. Sire of 70 ROM, 10 stakes win ners, earn ing , 079, 870, in clud ing FEA TURE MR JESS SI 101 4 wins, 2, 222, Rain bow Fut. G1, etc. ; , STREAKIN JESS PERRY SI 102 1723, Louisiana QHBA Fut. [R] G1, etc. ; , HOL LY WOOD PERRY SI 108 5, 016, Mardi Gras Fut. G2, etc. ; , HEZ NOT TOO SHABBY SI 104 3 wins, 3, 103 ; , CASH TO THE FRONT SI 104 5 wins, 4, 777 ; , etc. 1st dam: CEE BAR GIRL SI 97 1973 ; , by The Ole Man. 10 wins in 16 starts at 2, , 727, Mid-American Fut., Boomer Sooner Fut., 2nd Bluestem Downs Spring Fut., etc. Sis ter to CEE LADY BAR SI 106 , 540 ; , half-sis ter to Miss Re bel Guard. Dam of 16 foals, 15 to race, 10 ROM, Hexagonal SI 98 c. Streakin Six ; . 3 wins to 3, 4, 549, 2nd Fire cracker Fut. G1. Fi nal ist: All Amer i can Fut. G1, etc. ; . Sire. Mighty Cee Bar SI 95 g. Mighty Deck ; . 13 wins, 2 to 8, , 033. Sil i con SI 94 c. Streakin Six ; . 6 wins, 2 to 4 , 062, 2nd dam: Miss Re bel Girl SI 95, by Re bel Cause. 7 wins at 2, , 264, 2nd Live Oak D., 3rd Blue Rib bon Fut., ntr Blue Val ley Ranch Race track, 330 yds : 17.31. Dam of 10 foals, 10 to race, 7 ROM, CEE LADY BAR SI 106 f. by The Ole Man ; . 4 wins at 2 and 3, , 540, NEKQHA Fut., 2nd Flinthills D. Dam of 6 ROM, Ms Cee Bar Ap proach SI 94 f. Easy Ap proach ; . 2 wins at 3, , 794. CEE BAR GIRL SI 97 f. The Ole Man ; . Stakes win ner, see above. Miss Re bel Guard f. by Coldstream Guard ; . Win ner at 2, 3rd SEOKQHBA Fut. Dam of Cee Bar Johnie SI 88 c. Chickwego ; . 2 wins at 2, , 507, 3rd Old South Fut. See Bar Bug SI 93 g. Lady Bug's Moon ; . 5 wins at 2 and 5, , 542, 2nd Trin ity QHA Fut., etc. Miss Tarus Guard SI 95 f. Tarus Bar ; . 3 wins, to 3, , 053. Dam of JET AC TOR SI 89 f. Arbeka Jet One ; . 3 wins at 2 and 4, , 116, Flinthills Fut. Cee Bar Baby SI 94 f. The Ole Man ; . Win ner at 2, , 126. Dam of My Smashing Baby SI 87 f. Easily Smashed ; . 3 wins at 2, , 053. Dam of Royal Quick Smash SI 96 g. Royal Quick Dash ; . 6 wins, 2 to 4, , 726, 2nd Sooner Trailer Cal i for nia Chal lenge G3. Ms Di a mond Bar Baby SI 96 f. Marthas Six Moons ; . Win ner at 2 and 3, , 566. Fi nal ist: Hopes and Dreams Fut. [R] G3 ; . Race Re cord: Twice 3rd at 2, 2000. Earned , 512. En gage ments: MBNA Amer ica Racing Chal lenge Par ent age Ver ified - Cur rently in race train ing.

Ifosfamide emedicine

Peugeot 407 - picture shows Howard and his team in fancy dress. 1, 541 was raised through table top sales over the last year for Leeds Branch by the grand parents of Josef Wolstencroft who is four and has MG many thanks again for this support. John and Rose Kozyra held their annual square dance to support the Leeds Branch raising over 370, with chair Heather Read and her mum staffing stalls at various locations throughout the summer. Brighouse branch's stall at Brighouse Gala was a huge success - thanks to Richard and Dorothy plus all of the Committee who manned the stall throughout the day. South Yorkshire branch held their annual strawberry cream tea in July pictured right ; and thanks go to Sue and Chris Hudson and all the committee for making the day a huge success raising over 600. Beryl and Alan. D. The key to a successful nuclear medicine test is to remain as still as possible. The period of time you will need to remain still is approximately 16-25 minutes. If you feel that you cannot remain still or if you have any concerns about remaining still, please contact your patient care coordinator immediately. Due to the sensitivity of the radioisotope, payment will be required if you are unable to remain still, due to the need to reschedule that scan. E. Be sure to dress comfortably so that you are relaxed. Also, dress warmly since our imaging room may be chilly. F. Prepare yourself for a fairly lengthy visit. For the concentration study, your first scan appointment will last approximately 2 hours. For the resting study, your second scan appointment will last approximately 2 hours. Your SPECT Review which is scheduled approximately 14 days after your last scan, will last about 1 hour and iloprost. Previously unirradiated metastatic sites may be irradiated during Weeks 47-51 Age Dose 3 years 1.5 mg m2 IV x 1 maximum dose 2 mg ; 1 year and 3 years 0.05 mg kg IV x 1 maximum dose 2 mg ; 1 year 0.025 mg kg IV x 1 Irin Irinotecan Irinotecan 20 mg m2 IV maximum dose 40mg day ; daily x 5 I Ifosfamide Age 1 year: 1800 mg m2 day IV x 5 Age 1 year: treat with 50% doses calculated on a m2 basis.# E Etoposide Age 1 year: 100 mg m2 day IV x 5 Age 1 year: treat with 50% doses calculated on a m2 basis. # D Doxorubicin Age 1 year: 37.5mg m day x 2 days total dose 75 mg m ; Age 1 year: treat with 50% doses calculated on a m2 basis. # # If tolerated no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities ; , consider increasing to 75% and then to 100% of the calculated full dose. C Cyclophosphamide 3 years 1200 mg m2 IV x 1 years 40 mg kg IV x 1 Dactinomycin 1 year 0.045 mg kg IV x 1 maximum dose 2.5 mg ; 1 year 0.025 mg kg IV x 1 MESNA will be used with Cyclophosphamide and Ifosfamide. Filgrastim will be used in VAC, VDC, and IE cycles. See Section 8 for specific directions. Sargramostim or Peg-Filgrastim should not be used. If there is an age change during treatment use the new appropriate age dosing in the next cycle. V Vincristine give before Irinotecan.

Ifosfamide with mesna

BEGIN DECK 3 CONFIDENTIAL * NORC-4284 FOR OFFICE USE ONLY: ~ NATIONAL MULATORY MEDICAL CARE SURVEY INDUCTION INTERVIEW \Phy~. I~N~er I BEFORE STARTING INTERVIEW 1. ENTER PHYSICIAN I.D. NUMEER IN BOX TO RIGHT. I ~ and indinavir.
Special article - Infusion 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience. P.J. Ross, A. Webb, D. Cunningham et al. Review - Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trails. R. G Simonetti, A. Literati, C. Angioline et al. Commentary - AACR IARC meeting on carcinogenesis from environmental pollution, Budapest. P. Kleihues Arena: Point-counterpoint - Role of interferon as a modular of fluoropyrimidines: Reply to a recent editorial. S. Wadler & EL. Schwartz & reply R. Herrmann Original articles - Sexual dysfunctions in treated breast cancer patients. S. Barni & R. Mondin - Doubling epirubicin dose intensity in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. G. Brufman, E. Colajori, N. Ghilezan et al. Etoposide, intermediate-dose cytarabine and carboplatin: A combination therapy for blastic phase of chronic myelogenous leukemia. E. Montefusco, M. C. Petti, G Alimena et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. B. Glimelius, K. Ekstrom, K. Hoffman etal. High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A GISCAD phase III study. R. Labianca, S. Cascinu, L. Frontini et al. Post-remission therapy of adult actue myeloid leukaemia: One cycle of high-dose versus standard-dose cytarabine. M. Fopp, M.F. Fey, M. Bacchiet al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J. L. Pater, W. S. Lofters, B. Zee et al. - Clinical characteristics of severe peripheral neuropathy induced by docetaxel. P. H. E. Hilkens, J. Verweij, Ch. J. Vecht et al. Clinical case - Docetaxel and interstitial pulmonary injury. M. Merad et al. Short reports - Ifosfamide and paclitaxel salvage chemotherapy for advanced epithelial ovarian cancer. M.A. Dimopoulos et al. - Management of secretions in esophageal cancer patients with glycopyrrolate. H. Rashed et al. - The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. J. A. Burger et al. Letters - 5-fluorouracil-based treatment of patients with advanced colorectal carcinoma outside clinical trials: Importance of limited toxicity. H.K. van Halteren et al. - C.A. Presant et al. - L-Asparaginase-depletion: Another opinion. J. Baumgart et al.
This compound, TMC207, or J, is owned by Johnson & Johnson J&J ; and is being developed at its research subsidiary Tibotec. Tibotec scientists discovered J by screening their chemical libraries for compounds with anti-mycobacterial properties. The compound has many characteristics that make it an attractive TB drug candidate, including low molecular weight, high potency against drugsensitive and drug-resistant TB strains, very long half-life permitting once-weekly dosing ; , and low potential for drug interactions and infliximab.

Ifosfamide toxicity

Referenz 646 Neurologie, 11. Auflage ; Mattle HP, Wentz KU, Edelman RR, Wallner B, Finn JP, Barnes P, Atkinson DJ, Kleefield J, Hoogewoud HM. Cerebral venography with magnetic resonance. Radiology 178: 453-458, 1991 Department of Radiology, New England Deaconess Hospital, Boston, MA. The authors describe a two-dimensional time-of-flight magnetic resonance MR ; angiography technique to create projection venograms of the head. The technique was applied to 27 healthy volunteers and 39 patients. The superior sagittal and straight sinuses, the internal cerebral veins, and the Galen vein were visualized in all the volunteers. Other veins were seen in a high percentage of subjects. Systematic comparison of digital subtraction angiography DSA ; after intraarterial contrast medium injection and MR venography in patients showed good correlation between the two techniques. MR venography proved helpful in identifying thrombosis or patency of cerebral veins and sinuses and showed collateral venous drainage and venous drainage from arteriovenous malformations. There was good correlation between conventional contrast angiography and MR venography. In conclusion, MR venography is considered reliable for showing the cerebral venous system and provides information additional to that of conventional spin-echo imaging.

Concentrations in the clinical situation, especially in the case of repeated administration of higher doses of the sulfonamides, may be higher than estimated in this study, which may result in greater degrees of in vivo interactions. In this study, we systematically evaluated the inhibitory effects of sulfonamides on tolbutamide metabolism mediated by CYP2C9. This evaluation may also be applied to other drugs that are metabolized by CYP2C9. Therefore, attention should be paid in coadministration of sulfonamides with relatively small Ki values sulfaphenazole, sulfadiazine, sulfamethizole, and sulfisoxazole ; and CYP2C9 substrates with narrow therapeutic ranges such as phenytoin an antiepileptic ; and warfarin an anticoagulant and intal. N Centenary College has implemented a First-Year Experience Program that has involved 265 freshmen in a special academic track that is complemented by service learning. These students have had extensive community service participation over the past year working in the area of equine rescue, a local kindergarten, and a retirement community and at The Matheny School. n Drew University established a Retention Task Force that linked admissions, financial aid, academic affairs, student affairs, the graduate school, the registrar, institutional research, and the alumni offices. The Task Force has developed a Retention Marketing Program that is being rolled out institution-wide. n Georgian Court University has joined a highly selective initiative of the Policy Center for the First Year of College. This network of 300 institutions only offers membership to less than 20 new institutions per year. The Center's Foundations of Excellence program is a comprehensive, guided self-study process for evaluating and enhancing an institution's ability to realize its goals for student learning, success, and persistence to degree. It is based on a set of Foundation Dimensions that guide measurement of institutional efforts and provide an aspirational model for the entirety of the college experience from beginning contact with prospective students through admissions, orientation, the first-year curriculum, and the transition to second year. n The approach at Saint Peter's College is parent-centered in that so many of its incoming students are first generation college students and there is a need to orient the parents about the experience their sons and daughters will have as college students. This way, the parents can reinforce the college's retention goals. This project has included an expanded summer orientation that involves parents. A Parents' Webpage has been estab.

Generic Ifosfamide

Body weight of the treatment the administration body weight and invirase.
KNEE DAMAGE When I was 15, I damaged my left knee quite severely and as a result ended up with a very stiff joint and recurring pain especially if I did lots of exercise on it or when the weather started to get cold or rain was around. Since I started taking the flexibility for life product I have found that my knee is much more mobile, takes a lot more exercise stress and does not develop that pain in the joint when the weather starts to get inclement. I tried it for a month then ran out. Within a couple of days I found my knee again developing its old traits of stiffness, soreness and discomfort. When I received my new supply, I started taking the product once more and within 2 days, my knee problems disappearing yet again - what a relief. I can certainly recommend this product as I have experienced my knee condition whilst on and off the product. I can honestly say I prefer the way my knee feels whilst I taking this wonderful product. Wayne McCullough. Sional administration of cyclophosphamide compared to bolus dosing. Another pharmacodynamic aspect of this agent is the requirement for microsomal activation which may obscure possible differences between infusion and bolus administration. It is evident from these studies that for cyclophosphamide the dose intensity is comparable whether one uses an infusional delivery or bolus administration. lfosfamide The analogue of cyclophosphamide is most commonly administered as a daily bolus or as a continuous infusion over five days. In order to obviate the problem of hemorrhagic cystitis with bolus dosing, a common administration schedule is as a fractionated bolus daily for five days with concomitant Mesna administration. In a phase I study of 4-day continuous infusion ifosfamide along with Mesna uroprotection, dose escalation to a maximum dose of 18 g was possible and dose limiting toxicity was renal insufficiency and central nervous system toxicity [26]. For 10-day infusion periods, the maximum cumulative dose decreased to 12 to [27] and in a phase I trial of protracted infusion of ifosfamide for 14 days, the MTD was 7 g m2 per cycle [28]. Therefore, the MTD and DI for infusional ifosfamide may be increased or decreased relative to bolus delivery depending on the duration of infusion. Although phase III trials of infusional versus bolus ifosfamide have not been carried out, one study did analyze a sequential group of patients receiving ifosfamide as a bolus and subsequent entries as an infusion in conjunction with a combination chemotherapy regimen for metastatic sarcoma and there was a higher response rate in the group receiving bolus ifosfamide [29]. Thiotepa The alkylating agent thiotepa is uncommonly used but has been employed as an alkylating agent in the treatment of Hodgkin's disease replacing nitrogen mustard because of the absence of gastrointestinal toxicity and it has also been used as part of a combination chemotherapy regimen for breast cancer. Dose limiting toxicity for bolus administration is bone marrow suppression as it is for infusional delivery. Only a single phase I trial has been carried out for thiotepa using a continuous infusion schedule. The cumulative dose for a 5-day infusion is 60 mg m 2 and for the more protracted infusion of 28 days, the cumulative dose is almost doubled to 112 mg m 2 [30]. Therefore, for this particular alkylating agent, the MTD and dose intensity is increased by a factor of 4 to the infusion schedule compared to the bolus schedule. Platinum analogues The two major platinum analogues are cisplatin and carboplatin, each of which demonstrate a different dose limiting toxicity and toxicity which is generally not altered with the use of the infusional schedule. For cisplatin, the continuous infusion schedule was introduced as a potential option for decreasing extra-medullary toxicity such as renal, neurologic toxicity and gastrointestinal toxicity [31]. However, the same pattern and frequency of toxicities are observed on the infusional schedule as the bolus schedule and the doses achieved per cycle are similar with a comparable dose intensity. For carboplatin, the dose limiting toxicity is bone marrow suppression with markedly reduced gastrointestinal and renal toxicity compared to cisplatin. Bolus dosing is commonly guided by the Calvert formula and the MTD for bolus scheduling varies between 400 and 600 mg m2 and could be higher. The infusional schedule has been explored in a phase I study with a decrease in the cumulative dose per cycle and a modest decrease in the dose intensity [32]. Other studies of continuous infusion carboplatin have suggested that the dose intensity may in fact be increased. For example, in the study by Smit et al. [33], the cumulative dose for a 21-day infusion was 630 mg m2. However, because of the delayed pattern of hematologic toxicity associated with carboplatin, this infusional schedule could only be administered at 6-week intervals. Thus, the dose intensity is calculated to be approximately 105 mg m 2 which is comparable or slightly less than that achieved with bolus administration depending upon the Calvert formula calculation. The trials of continuous infusion carboplatin in refractory leukemia utilized a cumulative dose of 1500 mg m 2 per cycle [34]. Although demonstrating activity in acute leukemia, the precise calculation of the dose intensity for carboplatin is complicated by the pattern of delayed and protracted myelosuppression. Nonetheless, assuming an interval of up to weeks between cycles of treatment, the potential dose intensity nearly doubles to 200 mg m 2 per week with infusional delivery compared to bolus administration at least in the trials involving carboplatin for leukemia and iressa.

Ifosfamide research

Recommendations are based upon the following protocols: B-precursor standard risk--Children's Cancer Group CCG ; 1991; B-precursor high risk--CCG 1961; B-precursor very high risk--Children's Oncology Group COG ; AALL0031; infants--CCG 1953; and T cell--COG AALL00P2. Abbreviations: ARA-C cytosine arabinoside Cytosar-U ASPARA L-asparaginase Elspar CR XRT cranial radiation therapy; CYCLO cyclophosphamide Cytoxan DAUNO daunorubicin Cerubidine DEXA dexamethasone; DOXO doxorubicin Adriamycin ETOP etoposide VePesid ; 1; HDARA-C high-dose cytosine arabinoside; HDMTX high-dose methotrexate; HSCT hematopoietic stem cell therapy; IDMTX intermediate dose methotrexate; IFOS ifosfamide Ifex ; 1; IT intrathecal; ITT triple drug intrathecal methotrexate, hydrocortisone, cytosine arabinoside MP 6-mercaptopurine Purinethol MTX methotrexate, PEG-ASPARA peg-asparaginase Oncaspar PRED prednisone; STI571 imatinib Gleevec ; 1; TG 6-thioguanine Tabloid VCR vincristine Oncovin VHDMTX veryhigh-dose methotrexate. 1 Not FDA approved for this indication and ifosfamide. Ifex ifosfamide ifex drug interactions compare ifex with other medications for the treatment of: testicular cancer user reviews: 0 comment s ; about ifex services a to z drug list drugs by condition drug side effects pill identifier interactions checker news & articles new drug approvals new drug applications fda drug alerts clinical trial results drug image search patient care notes medical encyclopedia medical dictionary medical videos - drug classification community forums for professionals drug imprint codes medical abbreviations veterinary drugs contact us news feeds advertise here recent searches clomid namenda azasite zyrtec ativan arthrotec viagra propecia lipitor xenical ephedrine magnevist zelnorm enablex humalog propranolol vectibix recently approved pristiq arcalyst xyntha simcor accretropin moxatag tekturna hct intelence recothrom flo-pred more and irinotecan.
In March all caving access rights for Football Field Quarry also known as No.4 ; and Quarry Dean Farm also known as No.2 ; in East Surrey were removed by the landowners. The situation is very delicate, please do not attempt to visit these sites the landowners have signalled a willingness to prosecute ; , and leave all negotiations to the Wealden CMS and the CSCC. Browne's Folly Mine Browne's Folly Mine at Bathford has been closed by the Avon Wildlife Trust pending a condition report by a Mines Inspector. The CSCC is being kept informed. Cavers are asked to stay away until further notice. Avelines Hole A gate has been installed at the very back of Avelines Hole in Burrington Coombe. A rock carving of possibly Mesolithic origin has been discovered. More details can be found on the UBSS website. Box Stone Mine Following consultations with the landowners, English Nature - who have a statutory duty to protect the resident bat colonies - have informed the CSCC of forthcoming works at Box Stone Mine, near Bath, later this year. There are no longer to be any open entrances. Some will be filled in, some will grilled and some will be gated. Caving access will be preserved. Further details will be posted as they become available.

Discount Drugs

Medline items on this article's topics can be found at : highwire anford lists artbytopic.dtl on the following topics: Cell Biology . Myocytes Physiology . Contractility Physiology . Rats Updated information and services including high-resolution figures, can be found at: : ajpheart.physiology cgi content full 280 4 H1916 Additional material and information about AJP - Heart and Circulatory Physiology can be found at: : the-aps publications ajpheart and isdn. Field of the invention the present invention comprises the discovery of lyophilized ifosfamide compositions having improved properties over previously disclosed pharmaceutical compositions and lyophilizates and iloprost.

We thank to Dr. K. Kawahara Kumamoto University ; for helpful suggestions. This work was supported by grants-in-aid for scientific research from the Ministry of Health, Labor, and Welfare of Japan as well as by the Suzuken Memorial Foundation, the Tokyo Biochemical Research Foundation, Kumamoto Technology and Industry Foundation, and the Japan Research Foundation for Clinical Pharmacology. Article, publication date, and citation information can be found at : molpharm etjournals . doi: 10.1124 mol.106.027698 and isradipine.

Ifex mesna ifosfamide

Etoposide ifosfamide

Gray matter quotes, oxcarbazepine withdrawal symptoms, asymmetric crying facies in infancy, skin tag versus wart and end stage renal disease complications. Silver bullet drug, cafergot interactions, dendritic cell formation and burn treatment costs or vitamin d fibromyalgia.

Buy Ifosfamide

Iffosfamide, ifosfamied, ifoosfamide, ifosfaamide, ifosfaide, ifosfamie, ifostamide, ifofsamide, fiosfamide, ifosfamidf, ifosfakide, ifoafamide, irosfamide, ivosfamide, jfosfamide, ifosfamixe, ifosfamidr, ifisfamide, ifoscamide, ifosfamode.

Ifosfamide prescribing information

Ifosfamide emedicine, ifosfamide with mesna, ifosfamide toxicity, generic ifosfamide and ifosfamide research. Ifosfamide long term effects, Discount Drugs, ifex mesna ifosfamide and etoposide ifosfamide or buy ifosfamide.

Free Web Hosting